Antibody-Drug Conjugates in Triple Negative Breast Cancer

KESKİNKILIÇ M., Sacks R.

Clinical Breast Cancer, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1016/j.clbc.2024.01.008
  • Dergi Adı: Clinical Breast Cancer
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Anahtar Kelimeler: ADC, Sacituzumab govitecan, TNBC, Trastuzumab deruxtecan, Trop-2
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer. It is a heterogeneous breast cancer subtype with a poor prognosis. Given these negative features, there is a need for new treatment options beyond conventional chemotherapy in both the early stage and palliative setting. Impressive results have been reported with antibody-drug conjugates (ADCs) that link a cytotoxic payload to a monoclonal antibody, such as sacituzumab govitecan and trastuzumab deruxtecan, in the metastatic stage. The focus of this review is to discuss completed and ongoing trials involving ADCs in TNBC.